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Side effects of antiviral drugs might be circumvented by their selective delivery into infected cells. This 
targeting can be obtained by conjugation of the drugs to macromolecules which are taken up specificaIly 
by the infected cells. The experiments reviewed, on this approach to antiviral chemotherapy, are mainly 
directed at improving the chemotherapeutic index of adenine arabinoside (ara-A) in the treatment of 
chronic hepatitis B by its coupling to gaiactosyl terminating glycoproteins. 
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I. INTRODUCTION 
In the therapy of some diseases (e.g., tumors, in- 
fections caused by intracellular microorganisms~ 
drug side effects might be circumvented by selec- 
tively delivering the drugs into those ceils where 
their action is required. This can be obtained by 
conjugating the drug to a macromolecular vector 
which is specifically taken up by target cells. In 
these cells conjugates will be pharmacologically ef- 
fective if the bond linking the drug to the carrier 
does not suppress the activity of the drug or if the 
bond is broken down in lysosomes with consequent 
intra~elIular elease of the drug. According to this 
rationale several attempts have been made in re- 
cent years to selectively deliver drugs or toxins to 
neoplastic cells by binding them with appropriate 
carriers mainly with antibodies against cancer- 
specific antigens (for reviews see [l-4]). Here we 
briefly report experiments where a similar ap- 
proach was applied to the antiviral chemotherapy. 
Inhibitors of DNA synthesis were selectively 
transported to deoxyribovirus-infected macro- 
phages or hepatocytes by conjugation with albu- 
min or with galactosyi-terminating glycoproteins, 
respectively. Protein conjugates can be active only 
in cells in direct contact with plasma (endothelial 
cells, cells of organs with sinusoid-type capillaries) 
since the wall of non-sinusoid capillaries is a bar- 
Adenine arabinoside Hepatitis B 
Asialog~ycoproie~n receptor 
rier for proteins and does not allow the conjugates 
to come into contact with the surface of other cells. 
For this reason, chronic hepatitis B infection ap- 
pears to be a good target for this approach to an- 
tiviral chemotherapy because in this disease virus 
growth takes place only in hepatocytes which are in 
contact with plasma. The experiments were con- 
sequently mainly directed at selectively delivering 
adenine arabinoside, which is an antiviral drug 
used in chronic hepatitis 3, into hepatocytes. 
2. ALBUMIN CONJUGATES 
The idea to selectively deliver antiviral drugs to 
infected macrophages by conjugation with 
albumin arose from the finding that the toxic pep- 
tide amanitin [5-7] after conjugation with this 
protein 181, changed its originai target 
(hepatocytes~ and produc.ed the typical nuclear 
changes [9,10] in cells endowed with high 
pinocytotic activity such as sinusoidal liver cells 
(endothelial cells and Kupffer cells) [ll], 
macrophages cultured in vitro [12,t3] and prox- 
imal convoiuted tubule cells of rat kidney [14]. 
Amanitin-albumin conjugate probably exerts its 
damaging action by releasing the toxin after 
penetration into the cells and digestion of the 
albumin moiety in lysosomes [ 11,151. The 
possibility was therefore considered that other 
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drugs, covalently linked to albumin, might be 
released in an active form after penetration of the 
conjugates into the cells [13,16]. If the drugs are 
selective inhibitors of DNA synthesis, the con- 
jugates should hinder the replication of DNA 
viruses in macrophages without damaging these 
cells as they do not divide, and should not affect 
proliferating cells which do not take up albumin 
[171. 
Two inhibitors of DNA synthesis, 5-fluoro- 
deoxyuridine (FUDR) and cytosine arabinoside 
(ara-C) were conjugated to rabbit serum albumin 
(RSA) by carbodiimide coupling. In experiments in 
vitro it was found that FUDR-RSA and ara- 
C-RSA kill pinocytosing and proliferating cells 
[16,17]. Thymidine and deoxycytidine, which are 
known to remove the effects of FUDR and ara-C, 
respectively [18], counteracted the action of 
FUDR-RSA and ara-C-RSA, indicating that the 
activity of the conjugates is due to the FUDR and 
ara-C moieties. Most probably the drugs are 
released free into the cells; in fact the bonds link- 
ing them to albumin involve their primary hydrox- 
yl groups [19], which must be phosphorylated for 
the drugs to be able to block DNA synthesis [18]. 
Mice infected with Ectromelia virus, the agent of 
mousepox, were chosen as an experimental model 
to study the antiviral activity of these conjugates in 
vivo [17]. Ectromelia virus, when injected in- 
travenously into mice, is ingested mainly by the 
Kupffer cells where it replicates. After about 12 h 
it infects neighbouring hepatocytes which in turn 
infect more hepatic cells after each cycle of growth 
[20,21]. The effect of FUDR-RSA and ara- 
C-RSA on virus growth in vivo was evaluated ac- 
cording to two criteria: inhibition of virus produc- 
tion in liver, and survival time and number of sur- 
vivors. The conjugates, injected into mice at the 
same time as purified Ectromelia virus, reduced 
the virus yield in liver by l-2 logs 48 h after infec- 
tion, whereas free FUDR and ara-C were com- 
pletely ineffective. Moreover ara-C-RSA 
significantly increased the mean survival time of 
infected mice and the number of survivors. The 
conjugates were inactive or only slightly active if 
administered 12 or 24 h after infection, when virus 
replication occurs in hepatocytes. These results in- 
dicate that the conjugates interfere mainly with the 
phase of virus infection which takes place in liver 
macrophages. 
3. ASIALOFETUIN CONJUGATES 
Albumin conjugates of inhibitors of DNA syn- 
thesis can not be used in viral diseases of man 
because the growth of deoxyriboviruses in human 
macrophages (poxviruses) occurs only in a pre- 
symptomatic stage, when therapy can not be 
started. However, the results obtained with 
albumin conjugates of ara-C and FUDR suggested 
[17,22] a similar approach for the treatment of 
human chronic hepatitis B, in which the virus 
replicates in hepatocytes. Inhibitors of DNA syn- 
thesis can be coupled to glycoproteins which, after 
removal of sialic acid and consequent exposure of 
galactosyl residues, are selectively taken up by 
hepatocytes where they are digested in lysosomes 
[23-291. Trifluorothymidine (FjT), an inhibitor of 
DNA synthesis which is active in mice in very low 
doses and can be easily conjugated to proteins, was 
linked [22] to desialylated fetuin, a carrier which 
has been previously used to deliver proteins [30] 
and liposomes [31] to parenchymal liver cells. F3T 
was first converted to its glutarate which was 
subsequently coupled via its hydroxysuccinimide 
ester to c-NH2 groups of lysine residues of asialofe- 
tuin (AF). The molar ratio F3T:AF in the con- 
jugate was 8. Coupling with F3T did not change the 
ability of AF to interact with the specific receptors 
on the surface of hepatocytes. Indeed, the 
clearance of 14C-labelled AF from mouse blood 
was inhibited to the same extent by F3T-AF or by 
an equal amount of non-conjugated AF. F3T and 
F3T-AF were injected in mice 44 h after Ec- 
tromelia virus infection and their effect on 
deoxy[5-3H]cytidine incorporation into DNA was 
determined in liver and in bone marrow [22]. 
Forty-four h after Ectromelia virus infection the 
greater part of deoxycytidine incorporation in liver 
is probably due to virus DNA synthesis [22,32] 
most of which occurs in hepatocytes [32]. In liver, 
F3T coupled to AF caused inhibitions of deoxy- 
cytidine incorporation 3-times higher than those 
produced by equal doses of the free drug. On the 
contrary, in bone marrow the free or coupled drug 
inhibited the incorporation to the same extent. 
This result indicates that after injection of the con- 
jugate, F3T is concentrated in a pharmacologically 
active form in liver. Evidence has been obtained 
[22] that the inhibition of DNA synthesis in bone 
marrow of mice, injected with FjT-AF. was due to 
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F3T which after release from the conjugate in 
hepatocytes escaped from these cells into the blood 
as a free drug. 
F3T is a very toxic compound and is not used as 
a systemic drug in man. Therefore in subsequent 
experiments, adenine-9-P-D-arabinofuranoside 
(ara-A), which is a less toxic inhibitor of DNA syn- 
thesis, was coupled to AF [33]. Ara-A has been 
used in recent years in the treatment of chronic 
hepatitis B. It reduces, in a dose-dependent 
fashion, the serum levels of virus DNA-polymerase 
[34-381, with a loss of infectivity [39] and an 
overall improvement of liver disease [40] in some 
patients. However, ara-A also produces side- 
effects, mostly gastrointestinal and neurological 
disturbances [41,42]; at doses higher than 
25 mg.kg-‘.day-‘, it also causes severe depres- 
sion of bone marrow functions [43]. 
Two different coupling procedures were 
employed to conjugate ara-A with AF. In the first, 
ara-A glutarate was linked to the e-NH2 lysine 
groups of AF via its hydroxysuccinimide ster. The 
molar ratio ara-A : AF in this conjugate was 8. In 
the second procedure ara-A monophosphate (ara- 
AMP) was coupled to AF using a water soluble 
carbodiimide. In this coupling ara-A is linked to 
AF probably by the formation of a phosphoamide 
bond between the c-NH2 lysine groups of the pro- 
tein and the phosphate group of ara-AMP. The 
molar ratio ara-A: AF was 4. Conjugation with 
ara-A glutarate or ara-AMP did not change the 
ability of AF to interact with the specific receptors 
on the surface of hepatocytes. 
Free ara-A, free ara-AMP and ara-A conjugates 
were injected in mice 44 h after Ectromelia virus 
infection and their effects on thymidine incorpora- 
tion into DNA in liver and intestine were determin- 
ed [33]. Since ara-A is more than loo-times less ac- 
tive in rodents than in primates due to its rapid in- 
activation [44], infected mice were also given 
2’ -deoxycoformicin, which blocks ara-A deamina- 
tion [45,46] in order to obtain an inhibition of 
DNA synthesis by free or conjugated ara-A. The 
inhibition of DNA synthesis in liver produced by 
free ara-A or ara-AMP ranged from 42-77% ac- 
cording to the doses administered. Greater inhibi- 
tions (60-89%) were found in intestine. On the 
contrary, AF conjugates of ara-A inhibited DNA 
synthesis in liver (26-59%) but produced only 
small inhibitions in the intestine (O-19%). 
a 
4. LACTOSAMINATED ALBUMIN 
CONJUGATES 
A drawback for the clinical use of AF con- 
jugates of ara-A is their immunogenicity. These 
conjugates are strong inducers of antibodies [47] 
which can both inactivate the conjugates and pro- 
duce allergic lesions. This problem may be over- 
come by using lactosaminated homologous (i.e., of 
same species) albumin as hepatotropic carrier of 
ara-A. Some years ago it was suggested [48,49] 
that a protein may be made to penetrate into a cell 
which it can not normally enter alone by coupling 
it with a smaller molecule for which a specific 
binding site exists on the cell membrane. This 
hypothesis received experimental support from in- 
dependent experiments which showed that pro- 
teins, after coupling to small sugar molecules, 
penetrate selectively into cells which possess sur- 
face receptors for the coupled carbohydrates 
[26,30,50,51]. In this context it was found that 
galactosylated proteins, e.g., lactosaminated 
serum albumins (L-SA), enter specifically into 
hepatocytes after binding to the receptor for 
galactosyl-terminating lycoproteins [26,52]. To 
ascertain whether L-SA can substitute AF for liver 
targeting of ara-A, this drug was linked to rabbit 
and to human L-SA by carbodiimide coupling and 
the experiments described for ara-A-AF were 
repeated with these conjugates [32,53]. Various 
doses of free ara-A, free ara-AMP and L-SA con- 
jugates were injected in Ectromelia virus-infected 
mice and their effect on thymidine incorporation 
into DNA was determined in liver, intestine [32,53] 
and in some experiments in bone marrow [32]. In 
animals injected with free drugs, according to the 
different doses administered, the inhibitions of 
DNA synthesis ranged from 25-50% in liver, from 
31-62% in intestine and from O-43% in bone 
marrow. In animals injected with the coupled drug 
the percentages of inhibition in the same organs 
were 21-58%, O-23% and O-2%, respectively. 
The amounts of ara-A required to inhibit DNA 
synthesis in liver were about lo-times smaller when 
the compound was conjugated with L-SA than 
when it was administered as a free drug [53]. These 
results indicate that, after injection of L-SA con- 
jugates, ara-A is concentrated in an active form in- 
to hepatocytes. On the contrary to conjugates 
prepared with AF or with heterologous lac- 
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tosaminated albumin, ara-A conjugates prepared 
with homologous lactosaminated albumin are 
completely devoid of humoral and cellular im- 
munogenicity in mice [47]. Provided that the same 
immunological tolerance is true in man, human 
lactosaminated albumin appears to be the ap- 
propriate carrier to obtain liver targeting of ara-A 
in the treatment of chronic hepatitis B. In contrast 
to the naturally occurring glycoproteins of human 
blood, which after desialylation are also taken up 
by hepatocytes [24], human lactosaminated 
albumin can be easily obtained in the amounts re- 
quired for clinical use of the conjugates. L-SA con- 
jugates of ara-A do not display acute toxic effects, 
at least in mice. Administration of doses 11-times 
higher (the maximum tested) than those which pro- 
duce a 50% inhibition of virus DNA synthesis in 
liver of Ectromelia virus-infected mice, did not 
cause any recognizable signs of toxicity in mice 
[47]. Chronic toxicity with these conjugates has 
not yet been studied. In subsequent experiments 
[53] the hepatic rate of uptake of two L- 
(human)SA (L-HSA) preparations with 22 and 40 
galactosyl residues, respectively, was measured in 
mice. It was found that the maximal quantities of 
L22-HSA and of LK,-HSA which can enter into 
mouse liver are 0.24 and 0.26pg.g body 
wt-’ . min-‘, respectively. At plasma concentra- 
tions saturating the hepatic receptor, L22-HSA 
penetrates almost exclusively into the liver, only 
very small quantities being taken up by the cells of 
intestine, spleen and kidney. Uptake by other 
organs was not studied. In the case of LdO-HSA, a 
non-negligible amount of glycoconjugate is also 
taken up by the kidney. This finding indicates that 
L22-HSA is a better carrier than L40-HSA for liver- 
targeting of drugs. 
For the treatment of chronic hepatitis B [34-371 
as well as other infections caused by DNA viruses 
[43,44], free ara-A is given by continuous infusion 
at a dose usually of 15 mg. kg-‘. 12 h-’ which 
corresponds to 21 ng.g-‘.min-‘. Since the 
amounts of ara-A required to inhibit DNA syn- 
thesis in liver are about lo-times smaller when the 
drug is coupled to L-HSA (see above), the dose of 
conjugated ara-A which should be given to pa- 
tients with chronic hepatitis B is 2.1 ng. g body 
wt-’ . min-‘. In a conjugate with a molar ratio of 
ara-A to Lz-HSA of 11 (as in the conjugates 
usually prepared [53]), 2.1 ng ara-A is bound to 
0.055 Fg L22-HSA. According to the data reported 
above, L22-HSA enters into mouse liver at a rate of 
0.24 pg. g body wt-’ . min-‘. Therefore, provided 
that human hepatocytes infected by hepatitis B 
virus have a similar capacity for L22-HSA uptake 
as mouse hepatocytes, this carrier should be able to 
transport to such cells the dose of ara-A required 
to exert antiviral activity. 
5. CONCLUSIONS 
The experiments reported above provide 
evidence that antiviral agents can be selectively 
delivered into infected cells by conjugation with 
protein carriers. As far as potential applications of 
conjugates for the treatment of viral diseases in 
man are concerned, the experiments on ara-A con- 
jugates in Ectromelia virus infected mice lend sup- 
port to the hope of increasing the 
chemotherapeutic index of this drug in the treat- 
ment of chronic hepatitis B by its coupling to lac- 
tosaminated albumin. 
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